ACR honors NYU Langone professor with Distinguished Basic Investigator Award

Recognized by American College of Rheumatology for outstanding contributions and dedication to field

Steven B. Abramson, MD, senior vice president and vice dean of education, faculty and academic affairs and professor, Departments of Medicine and Pathology at NYU Langone Medical Center received the Distinguished Basic Investigator Award at the American College of Rheumatology (ACR) & Association of Rheumatology Health Professionals (ARHP) annual scientific meeting this week in Chicago.

The Distinguished Basic Investigator Award is a one-time, merit-based award presented each year by the ACR to a basic scientist in recognition of their research and contributions to the field of rheumatology.

Dr. Abramson is director of the Division of Rheumatology at the NYU School of Medicine and co-director, Center of Excellence on Musculoskeletal Disease at NYU Langone. A summa cum laude, Phi Beta Kappa graduate of Dartmouth College, Dr. Abramson earned his MD from Harvard Medical School, and was elected to the Alpha Omega Alpha honor society. Dr. Abramson joined the NYU School of Medicine faculty in 1979, achieving the level of professor in 1996.

Dr. Abramson is internationally recognized for basic science and clinical research in the field of inflammation and arthritis, and has published more than 200 papers in peer reviewed journals including Nature, Science, Osteoarthritis and Cartilage, Clinical Rheumatology and Annals of Rheumatic Diseases. He is a co-editor of the journal Arthritis & Rheumatism, a former member of the Rheumatology Board of the American Board of Internal Medicine (ABIM), immediate past president of the Osteoarthritis Research Society International (OARSI) and former chairman of the Arthritis Advisory Committee of the Food and Drug Administration (FDA). Dr. Abramson was appointed by the American College of Rheumatology (ACR) board of directors as the first chair of the ACR-FDA Drug Safety Committee. He is also a current member of the Skeletal Biology Structure and Regeneration Study Section of the National Institutes of Health (NIH).


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
EULAR's new strategy for 2024 - 2028 announced